膜性心力衰竭:不断发展的药理学方法
Kieran F Docherty1, Catherine M Otto2, John J V McMurray1
1BHF Cardiovascular Research Centre, School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland G12 8TA, UK.
European heart journal
|January 13, 2026
概括
心力衰竭和门疾病是密切相关的,每一种情况都会影响另一个. 本综述探讨了预防门疾病和管理心力衰竭患者的医疗治疗方法.
科学领域:
- 心脏病学 心脏病学
- 内部医学 内部医学
背景情况:
- 膜心脏病和心力衰竭有着复杂的双向关系.
- 心力衰竭是门疾病的常见原因和后果.
研究的目的:
- 审查膜心脏病中医学疗法的证据.
- 探索预防门疾病进展的治疗方法.
- 检查初级和二级门疾病中心力衰竭的治疗方法.
主要方法:
- 医学治疗证据的文献综述.
- 对门疾病和心力衰竭的治疗策略的分析.
主要成果:
- 证据支持用于管理门疾病的医疗治疗.
- 疗法可以预防疾病的进展,治疗心力衰竭.
- 具体的治疗方法因原发性与二次性门疾病而异.
结论:
- 医疗治疗在治疗患有门疾病和心力衰竭的患者中起着至关重要的作用.
- 综合性治疗策略对于改善患者的治疗结果至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915
Heart Failure V: Medical Management
209
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
209
Heart Failure Drugs: β-Blockers
758
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
758
Cardiomyopathy V: Interprofessional Care
331
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
331
Heart Failure VI: Adjunct Therapies
246
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
246
Aortic Regurgitation III: Medical Management
388
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
388


